Active Ingredient History
Tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis and one of at least 113 total cannabinoids identified on the plant. Although the chemical formula for THC (C21H30O2) describes multiple isomers, the term THC usually refers to the Delta-9-THC isomer with chemical name (−)-trans-Δ9-tetrahydrocannabinol. THC is a lipid found in cannabis and, like most pharmacologically active secondary metabolites of plants, it is assumed to be involved in the plant's evolutionary adaptation, putatively against insect predation, ultraviolet light, and environmental stress. THC was first discovered and isolated by Israeli chemist Raphael Mechoulam in Israel in 1964. It was found that, when smoked, THC is absorbed into the bloodstream and travels to the brain, attaching itself to endocannabinoid receptors located in the cerebral cortex, cerebellum, and basal ganglia. These are the parts of the brain responsible for thinking, memory, pleasure, coordination and movement. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Pain (Phase 2)
Accidents, Traffic (Phase 4)
Acute Pain (Phase 2)
Affect (Phase 2)
Alcohol Drinking (Phase 4)
Alzheimer Disease (Early Phase 1)
Anxiety (Phase 2/Phase 3)
Appetite (Phase 2)
Back Pain (Phase 3)
Biological Availability (Phase 1)
Bipolar Disorder (Phase 1)
Cachexia (Phase 3)
Cancer Pain (Phase 3)
Cannabidiol (Phase 2)
Cannabis (Phase 4)
Chronic Pain (Phase 4)
Depression (Phase 2)
Depressive Disorder, Major (Phase 2)
Dronabinol (Phase 3)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 1)
Dysmenorrhea (Phase 2)
Endometriosis (Phase 2)
Epilepsy (Phase 1)
Essential Tremor (Phase 1/Phase 2)
Fatigue (Phase 2)
Fibromyalgia (Phase 2)
Glioblastoma (Phase 1/Phase 2)
Headache Disorders, Secondary (Phase 4)
Healthy Volunteers (Phase 1)
HIV Infections (Phase 2)
Marijuana Abuse (Phase 1)
Marijuana Use (Phase 1)
Migraine Disorders (Phase 4)
Mood Disorders (Phase 2)
Morbidity (Phase 2)
Mortality (Phase 2)
Multiple Sclerosis (Phase 1/Phase 2)
Nausea (Phase 2)
Neck Pain (Phase 3)
Neoplasms (Phase 3)
Osteoarthritis, Knee (Phase 2)
Pain (Phase 2)
Pain, Postoperative (Phase 2/Phase 3)
Pain Threshold (Phase 2)
Palliative Medicine (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pancreatitis, Chronic (Phase 2)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 1)
Postoperative Nausea and Vomiting (Phase 2/Phase 3)
Psychomotor Agitation (Phase 1)
Quality of Life (Phase 2)
Skin Absorption (Phase 1)
Sleep Wake Disorders (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Substance-Related Disorders (Phase 1)
Vaping (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue